How does Sitagliptin compare to GLP-1 receptor agonists in reducing inflammation, and what are the implications for managing diabetes-related complications?
Sunil JoshiExplorer
Sign Up to our social questions and Answers Engine to ask questions, answer people’s questions, and connect with other people.
Please briefly explain why you feel this question should be reported.
Please briefly explain why you feel this answer should be reported.
Please briefly explain why you feel this user should be reported.
Sitagliptin and GLP-1 receptor agonists both improve glycemic control, but GLP-1s may offer superior reduction in inflammation. This can be crucial in managing complications like cardiovascular disease in diabetes patients.